Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for NRIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
May 31, 2026 443.53M
February 28, 2026 540.73M
November 30, 2025 592.94M
August 31, 2025 428.83M
May 31, 2025 485.78M
February 28, 2025 549.68M
November 30, 2024 609.58M
August 31, 2024 448.05M
May 31, 2024 443.14M
February 29, 2024 243.99M
November 30, 2023 287.91M
August 31, 2023 258.85M
May 31, 2023 281.18M
February 28, 2023 277.15M
Date Value
November 30, 2022 309.14M
August 31, 2022 344.48M
May 31, 2022 297.28M
February 28, 2022 261.98M
November 30, 2021 295.72M
August 31, 2021 343.90M
May 31, 2021 386.02M
February 28, 2021 303.07M
November 30, 2020 281.15M
August 31, 2020 354.24M
May 31, 2020 173.50M
February 29, 2020 71.35M
November 30, 2019 37.72M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Monte Rosa Therapeutics, Inc. 621.10M
Gilead Sciences, Inc. 4.882B
TG Therapeutics, Inc. 552.25M
Cue Biopharma, Inc. 17.39M
Keros Therapeutics, Inc. 257.61M